To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Scientific result | Health ＆ life sciences | Bacteria
A team from I2BC (SBIGeM), in collaboration with DMTS, took advantage of flexizymes technology to elucidate the functioning of the synthases of cyclodipeptides, enzymes implicated in the synthesis of 2,5-diketopiperazines, compounds that represent an unequaled source of bioactive molecules for the pharmacopoeia.
2,5-Diketopiperazines (2,5-DKP), produced by fungi, bacteria, plants and animals, possess remarkable biological properties (antibacterial, antiviral, anticancer or anti-inflammatory) which make them very attractive for pharmacopoeia. Muriel Gondry's team (I2BC/SBIGeM) has been studying the bacterial biosynthetic pathways of these molecules for several years. 2,5-DKP are synthesized in several steps: firstly, the cyclodipeptide synthases (CDPS), discovered in 2009 by the team, produce cyclodipeptides, using the amino acids loaded on the transfer RNAs (AA-tRNA). These cyclodipeptides are then modified by other enzymes to form 2,5-DKP.Despite a low level of sequence identity and the existence of two subfamilies of CDPS, these enzymes all appear to use a similar mechanism, relying on the successive binding of two AA-tRNA substrates and the formation of successive aminoacyl- enzyme and dipeptidyl-enzyme intermediates. For each of the two AA-tRNA substrates, the region of the tRNA recognized by CDPS is unknown, although some studies suggest that this is the acceptor arm. This hypothesis was tested in the present study.For this purpose, researchers took advantage of flexizymes technology, developed by a Japanese team. Flexizymes are ribozymes (RNA possessing enzyme-like activity) capable of aminoacylating a wide variety of RNAs. Using this technology, implemented and adapted in the laboratory, the researchers produced and purified various shortened AA-tRNAs which were tested in vitro for their ability to be substrates for CDPS. They thus observed that molecules mimicking the acceptor arm of tRNAs (AA-microHx) (figure) are substrates as effective as AA-tRNAs, demonstrating that the acceptor arm of tRNAs is the only region necessary for the activity of CDPS.
The method developed in this study could be used for the mechanistic study of other enzymes using AA-tRNA as substrate. It should also allow the incorporation into cyclopeptides of unnatural analogues of amino acids via the synthesis by flexizymes of tRNA or micro-Hx loaded with these analogues which will then be tested as substrates of CDPS.
See also : https://www.i2bc.paris-saclay.fr/spip.php?article1449
N. Canu, C. Tellier, M. Babin, R. Thai, I. Ajel, J. Seguin, O. Cinquin, R. Vinck, M. Moutiez, P. Belin, JC. Cintrat, M. Gondry. Flexizyme-aminoacylated shortened tRNAs demonstrate that only the aminoacylated acceptor arms of the two tRNA substrates are required for cyclodipeptide synthase activity. Nucleic Acids Res. 2020, https://doi:10.1093/nar/gkaa903
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.